UBS Group’s Sage Therapeutics SAGE Stock Holding History

UBS Group’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-7,100	Closed	-$1.11M	–	8222
2018 Q2	$1.11M	Buy	+7,100	New	+$1.11M	﹤0.01%	3696
2017 Q4	–	Sell	-40,000	Closed	-$2.49M	–	8057
2017 Q3	$2.49M	Buy	+40,000	New	+$3.14M	﹤0.01%	2923
2016 Q4	–	Sell	-175,000	Closed	-$8.06M	–	7998
2016 Q3	$8.06M	Buy	+175,000	New	+$7.12M	﹤0.01%	1599

Other funds holding SAGE

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's SAGE Position: Q3 2025 in Review

UBS Group sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 88,333 shares — an estimated $806K sold.

UBS Group first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $5.71M in Q4 2021. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

UBS Group reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS Group sold 88,333 Sage Therapeutics shares in Q3 2025, an estimated $806K.
UBS Group first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
UBS Group's Sage Therapeutics position peaked at $5.71M in Q4 2021.
5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.